Magnitude Biosciences partnered with AB Biotek Human Nutrition & Health (ABB HNH), the global leader in yeast probiotics and postbiotics. Recently we had the pleasure of hosting Maria Tintoré and Carlos de Lecea from AB Biotek at our lab in Sedgefield, UK.
There is growing evidence on how health problems and diseases are linked to a disruption of our microbiota. The development of new probiotics and other products targeting the microbiome are critical to improve human health.
There are ethical challenges however in testing new probiotics in vivo. Most manufacturers rely on using mammals such as rodents to test whether their products can improve whole animal health. Rodent studies not only pose ethical concerns but are often expensive and take a long time to generate high quality data. The nematode worm C. elegans has many of the cell types found in humans, as well as a short life cycle, and is thus a more ethical as well as faster solution to study the impact of probiotics on whole organism health.
AB Biotek were seeking more ethical options for testing their products without compromising on the reliability of in vivo data. Magnitude Biosciences were the obvious partner for this work, providing a unique solution that generates high quality, rich, fast and reliable data quantifying the impact of probiotics, prebiotics, health supplements and drug compounds in whole organism health without the use of mammalian models.
Magnitude Biosciences worked with the AB Biotek HNH scientific team to design and implement novel techniques to measure the impact of combinations of yeast, bacteria and prebiotics on whole organism health more ethically.
You can read the full case study here showing how health supplement and probiotics manufacturers can ethically and more cost-effectively test their products in vivo: